(Q42836426)

8 November 2017

title

Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma (English)

1 reference

8 November 2017

main subject

peripheral neuropathy

1 reference

Paul G Richardson

1

1 reference

8 November 2017

publication date

1 November 2010

1 reference

Lancet Oncology Commission

8 November 2017

published in

1 reference

8 November 2017

volume

11

1 reference

8 November 2017

issue

11

1 reference

8 November 2017

page(s)

1014-1016

1 reference

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970248-5

7 January 2021

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970248-5

7 January 2021

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970248-5

7 January 2021

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970248-5

7 January 2021

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970248-5

7 January 2021

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970248-5

7 January 2021

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970248-5

7 January 2021

10.1016/S1470-2045(10)70248-5

Identifiers

DOI

1 reference

8 November 2017

1 reference